介入肿瘤学的新兴适应症:图像引导热消融治疗转移性非颈部淋巴结疾病的全面系统回顾。

IF 4.7 2区 医学 Q1 ONCOLOGY
Current Oncology Reports Pub Date : 2024-11-01 Epub Date: 2024-10-28 DOI:10.1007/s11912-024-01616-4
David-Dimitris Chlorogiannis, Georgios Charalampopoulos, Dimitra Kontopyrgou, Angelliki Gkayfillia, Melina Nikolakea, Roberto Iezzi, Dimitrios Filippiadis
{"title":"介入肿瘤学的新兴适应症:图像引导热消融治疗转移性非颈部淋巴结疾病的全面系统回顾。","authors":"David-Dimitris Chlorogiannis, Georgios Charalampopoulos, Dimitra Kontopyrgou, Angelliki Gkayfillia, Melina Nikolakea, Roberto Iezzi, Dimitrios Filippiadis","doi":"10.1007/s11912-024-01616-4","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Lymphatic node metastatic disease encompasses a distinct oncological entity which has been associated with poor prognosis. Image-guided thermal ablation has recently been proposed as a safe and alternative treatment for these lesions. The aim of this systematic review is to evaluate the pooled safety and efficacy of thermal ablation techniques for the treatment of oligometastatic non-cervical lymph nodal disease.</p><p><strong>Recent findings: </strong>A systematic search of the three major databases (MEDLINE, EMBASE, and CENTRAL) from inception to 30 December 2023 was conducted according to the PRISMA Guidelines. Observational studies reporting technical success, complications and oncologic outcomes were included. Meta- analysis was performed by estimating the pooled incidence rates and risk ratios by fitting random-effect models. Overall, 8 studies were included, comprising of 225 patients and 305 ablated LNMs and a median follow-up of 12 months. The combined data analysis showed that technical success after thermal ablation was 98% (CI: 95%-99%), major complication rate was 1% (CI: 95%-99%), pooled overall response rate was 72% (CI: 54%-87%), local tumor progression rate was 18% (CI: 8%-33%) and disease-free survival rate was 68% (CI: 51%-81%). No difference between radiofrequency ablation and cryoablation was found for every outcome during subgroup analysis. Image-guided percutaneous thermal ablation (with either radiofrequency ablation or cryoablation) is safe and effective for the treatment of oligometastatic LMN disease, however further studies to confirm these findings are still needed.</p>","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"1543-1552"},"PeriodicalIF":4.7000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Emerging Indications for Interventional Oncology: A Comprehensive Systematic Review of Image-Guided Thermal Ablation for Metastatic Non-cervical Lymph Node Disease.\",\"authors\":\"David-Dimitris Chlorogiannis, Georgios Charalampopoulos, Dimitra Kontopyrgou, Angelliki Gkayfillia, Melina Nikolakea, Roberto Iezzi, Dimitrios Filippiadis\",\"doi\":\"10.1007/s11912-024-01616-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>Lymphatic node metastatic disease encompasses a distinct oncological entity which has been associated with poor prognosis. Image-guided thermal ablation has recently been proposed as a safe and alternative treatment for these lesions. The aim of this systematic review is to evaluate the pooled safety and efficacy of thermal ablation techniques for the treatment of oligometastatic non-cervical lymph nodal disease.</p><p><strong>Recent findings: </strong>A systematic search of the three major databases (MEDLINE, EMBASE, and CENTRAL) from inception to 30 December 2023 was conducted according to the PRISMA Guidelines. Observational studies reporting technical success, complications and oncologic outcomes were included. Meta- analysis was performed by estimating the pooled incidence rates and risk ratios by fitting random-effect models. Overall, 8 studies were included, comprising of 225 patients and 305 ablated LNMs and a median follow-up of 12 months. The combined data analysis showed that technical success after thermal ablation was 98% (CI: 95%-99%), major complication rate was 1% (CI: 95%-99%), pooled overall response rate was 72% (CI: 54%-87%), local tumor progression rate was 18% (CI: 8%-33%) and disease-free survival rate was 68% (CI: 51%-81%). No difference between radiofrequency ablation and cryoablation was found for every outcome during subgroup analysis. Image-guided percutaneous thermal ablation (with either radiofrequency ablation or cryoablation) is safe and effective for the treatment of oligometastatic LMN disease, however further studies to confirm these findings are still needed.</p>\",\"PeriodicalId\":10861,\"journal\":{\"name\":\"Current Oncology Reports\",\"volume\":\" \",\"pages\":\"1543-1552\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Oncology Reports\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11912-024-01616-4\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/10/28 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01616-4","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/28 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

简介淋巴结转移性疾病是一种独特的肿瘤实体,与预后不良有关。最近,有人提出图像引导下的热消融是治疗这些病变的一种安全的替代疗法。本系统综述旨在评估热消融技术治疗少转移性非宫颈淋巴结疾病的安全性和有效性:根据《PRISMA 指南》,我们对三个主要数据库(MEDLINE、EMBASE 和 CENTRAL)进行了系统检索,检索时间从开始到 2023 年 12 月 30 日。纳入了报告技术成功率、并发症和肿瘤结果的观察性研究。通过拟合随机效应模型来估计汇总的发病率和风险比,从而进行元分析。总共纳入了 8 项研究,包括 225 名患者和 305 个消融的 LNM,中位随访时间为 12 个月。综合数据分析显示,热消融术后的技术成功率为98%(CI:95%-99%),主要并发症发生率为1%(CI:95%-99%),汇总总反应率为72%(CI:54%-87%),局部肿瘤进展率为18%(CI:8%-33%),无病生存率为68%(CI:51%-81%)。在亚组分析中,射频消融术和冷冻消融术的各项结果均无差异。图像引导下经皮热消融(射频消融或冷冻消融)治疗少转移LMN疾病是安全有效的,但仍需进一步研究证实这些结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Emerging Indications for Interventional Oncology: A Comprehensive Systematic Review of Image-Guided Thermal Ablation for Metastatic Non-cervical Lymph Node Disease.

Introduction: Lymphatic node metastatic disease encompasses a distinct oncological entity which has been associated with poor prognosis. Image-guided thermal ablation has recently been proposed as a safe and alternative treatment for these lesions. The aim of this systematic review is to evaluate the pooled safety and efficacy of thermal ablation techniques for the treatment of oligometastatic non-cervical lymph nodal disease.

Recent findings: A systematic search of the three major databases (MEDLINE, EMBASE, and CENTRAL) from inception to 30 December 2023 was conducted according to the PRISMA Guidelines. Observational studies reporting technical success, complications and oncologic outcomes were included. Meta- analysis was performed by estimating the pooled incidence rates and risk ratios by fitting random-effect models. Overall, 8 studies were included, comprising of 225 patients and 305 ablated LNMs and a median follow-up of 12 months. The combined data analysis showed that technical success after thermal ablation was 98% (CI: 95%-99%), major complication rate was 1% (CI: 95%-99%), pooled overall response rate was 72% (CI: 54%-87%), local tumor progression rate was 18% (CI: 8%-33%) and disease-free survival rate was 68% (CI: 51%-81%). No difference between radiofrequency ablation and cryoablation was found for every outcome during subgroup analysis. Image-guided percutaneous thermal ablation (with either radiofrequency ablation or cryoablation) is safe and effective for the treatment of oligometastatic LMN disease, however further studies to confirm these findings are still needed.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
8.50
自引率
0.00%
发文量
187
审稿时长
6-12 weeks
期刊介绍: This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信